VRTX Vertex Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VRTX

Price (delayed)

$329.99

Market cap

$84.99B

P/E Ratio

25.96

Dividend/share

N/A

EPS

$12.71

Enterprise value

$76.49B

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather ...

Highlights
Vertex Pharmaceuticals's net income has increased by 33% YoY
The equity has grown by 32% YoY and by 3.7% from the previous quarter
The EPS has increased by 33% year-on-year but it has declined by 2% since the previous quarter
The price to earnings (P/E) is 20% less than the 5-year quarterly average of 32.4 but 12% more than the last 4 quarters average of 23.1
Vertex Pharmaceuticals's quick ratio has decreased by 11% QoQ and by 10% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://www.vrtx.com/
Peers: GILD ABBV MRK BMY

Key stats

What are the main financial stats of VRTX
Market
Shares outstanding
257.55M
Market cap
$84.99B
Enterprise value
$76.49B
Valuations
Price to earnings (P/E)
25.96
Price to book (P/B)
5.88
Price to sales (P/S)
9.22
EV/EBIT
18.12
EV/EBITDA
17.5
EV/Sales
8.31
Earnings
Revenue
$9.21B
EBIT
$4.22B
EBITDA
$4.37B
Free cash flow
$3.89B
Per share
EPS
$12.71
Free cash flow per share
$15.11
Book value per share
$56.14
Revenue per share
$35.77
TBVPS
$67.14
Balance sheet
Total assets
$18.97B
Total liabilities
$4.54B
Debt
$789.2M
Equity
$14.43B
Working capital
$9.94B
Liquidity
Debt to equity
0.05
Current ratio
4.28
Quick ratio
3.95
Net debt/EBITDA
-1.94
Margins
EBITDA margin
47.5%
Gross margin
88%
Net margin
35.4%
Operating margin
43.4%
Efficiency
Return on assets
18.8%
Return on equity
24.5%
Return on invested capital
95.7%
Return on capital employed
26.5%
Return on sales
45.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VRTX stock price

How has the Vertex Pharmaceuticals stock price performed over time
Intraday
-0.79%
1 week
-3.43%
1 month
2.07%
1 year
22.38%
YTD
14.27%
QTD
4.74%

Financial performance

How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$9.21B
Gross profit
$8.11B
Operating income
$3.99B
Net income
$3.26B
Gross margin
88%
Net margin
35.4%
The operating income has grown by 36% year-on-year but it has declined by 6% since the previous quarter
Vertex Pharmaceuticals's net income has increased by 33% YoY
The operating margin has increased by 18% YoY but it has decreased by 9% QoQ
The gross profit has grown by 16% YoY and by 3.3% from the previous quarter

Growth

What is Vertex Pharmaceuticals's growth rate over time

Valuation

What is Vertex Pharmaceuticals stock price valuation
VRTX P/E details
P/E
25.96
P/B
5.88
P/S
9.22
EV/EBIT
18.12
EV/EBITDA
17.5
EV/Sales
8.31
The EPS has increased by 33% year-on-year but it has declined by 2% since the previous quarter
The price to earnings (P/E) is 20% less than the 5-year quarterly average of 32.4 but 12% more than the last 4 quarters average of 23.1
The equity has grown by 32% YoY and by 3.7% from the previous quarter
The stock's price to book (P/B) is 29% less than its 5-year quarterly average of 8.3 but 3.2% more than its last 4 quarters average of 5.7
The price to sales (P/S) is 17% less than the 5-year quarterly average of 11.1 but 7% more than the last 4 quarters average of 8.6
VRTX's revenue is up by 16% YoY and by 3.1% QoQ

Efficiency

How efficient is Vertex Pharmaceuticals business performance
The return on invested capital rose by 28% year-on-year but it has declined by 12% since the previous quarter
The return on sales has increased by 24% year-on-year but it has declined by 4.6% since the previous quarter
The return on equity has declined by 8% since the previous quarter
VRTX's return on assets is down by 8% since the previous quarter

Dividends

What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRTX.

Financial health

How did Vertex Pharmaceuticals financials performed over time
The total liabilities has increased by 36% YoY and by 7% QoQ
Vertex Pharmaceuticals's total assets has increased by 33% YoY and by 4.5% QoQ
VRTX's debt is 95% lower than its equity
The debt to equity fell by 38% YoY and by 17% QoQ
The equity has grown by 32% YoY and by 3.7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.